A Study of LY3819253 (LY-CoV555) in Participants Hospitalized for COVID-19

The purpose of this study is to test the safety and tolerability of LY3819253 when it is given by injection into a vein to participants hospitalized with COVID-19. Blood tests will be done to check how much LY3819253 is in the bloodstream and how long the body takes to eliminate it.

Trial Summary

Age Range
18 - 75 years
Conditions the trial is for
COVID-19
What the trial is testing?
Bamlanivimab
Could I receive a Placebo?
Yes
Enrollment Goal
26
Trial Dates
May 28, 2020 - Aug 26, 2020
How long will I be in the trial?
Participation could last about 8 weeks and may include up to 15 visits in the hospital or in the home.
Trial Phase
I

Lilly Trial Alerts

Not the right fit? Sign up to receive updates about new trials that are listed or when a new trial site begins enrolling near you.